By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug Administration granted regular approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc. [now a part of Pfizer Inc.]) for
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY The FDA gave its approval for the use of osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) alongside platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell
More
By: Dr. Anish ShahBronx-Lebanon Hospital; Bronx, NY On February 16, 2024, the U.S. Food and Drug Administration granted accelerated approval to lifileucel (Amtagvi). The approval targets adults with metastatic or inoperable melanoma who
More
By: Dr. Anish ShahBronx-Lebanon Hospital; Bronx, NY On February 15, 2024, the U.S. Food and Drug Administration granted regular approval to tepotinib (Tepmetko) for adult patients with metastatic non-small cell lung cancer (NSCLC)
More
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On February 13, 2024, the U.S. Food and Drug Administration granted approval for the use of irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) as a combined treatment
More
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On December 13, 2023, the U.S. Food and Drug Administration granted approval to eflornithine (IWILFIN, USWM, LLC) for adult and pediatric patients with high-risk neuroblastoma (HRNB)
More
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY The U.S. Food and Drug Administration gave its approval for the use of enfortumab vedotin-ejfv (Padcev, Astellas Pharma) in combination with pembrolizumab (Keytruda, Merck) as a
More
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On December 14, 2023, the U.S. Food and Drug Administration granted approval to belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma
More
By Dr. Arya Mariam Roy of Roswell Park Comprehensive Cancer Center Tucatinib, a HER2-directed tyrosine kinase inhibitor (TKI), has been approved in combination with trastuzumab and capecitabine for previously treated HER2+ metastatic
More
By Dr. Arya Mariam Roy of Roswell Park Comprehensive Cancer Center Development of endocrine resistance remains a challenge in the management of HR-positive HER2-negative breast cancer (HR+ HER2- BC). Alterations in PI3K
More
By Dr. Shipra Gandhi of Roswell Park Comprehensive Cancer Center Data from two phase III trials showed that adding immune checkpoint inhibition in the neoadjuvant setting in HR positive breast cancer was
More